drugset
drugset / Trial / NCT00785408

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

NCT00785408 ↗

Phase 2 Completed 273 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.

Timeline

Start
2008-12
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject DAVALINTIDE Protein / enzyme biologic — Subcutaneous

Indications

obesity disorder